Pharmaceuticals, Biotechnology and Life Sciences
Boehringer Ingelheim has reported that final results from RE-VERSE AD study showed that idarucizumab, marketed in the U.S. as Praxbind, was able to immediately reverse the anticoagulant effect of Pradaxa (dabigatran etexilate mesylate) in patients in emergency situations.
Evgen Pharma said Tuesday that its lead product, SFX-01, will be tested against triple negative breast cancer (TNBC) in new preclinical research at the Manchester Cancer Research Centre, UK.
Sanofi announced today it will acquire Protein Sciences, a privately held vaccines biotechnology company based in Meriden, Connecticut in the United States.
Norwegian pharmaceutical company Vistin Pharma ASA has entered a Sales and Purchase agreement with independently-owned Australian company TPI Enterprises Limited for its opioids and tablet manufacturing business.
Guerbet, the global specialist in contrast products and solutions for medical imaging, will phase out sales throughout the world of two products: Hexabrix (meglumine and sodium ioxaglate) and Optimark (gadoversetamide).
BioInvent International and ThromboGenics have agreed to amend their long-standing agreement, which covers the co-development of the novel anti-PlGF monoclonal antibody products TB-403 and THR-317.
Celgene Corporation and BeiGene have entered into a strategic collaboration to develop and commercialize BeiGene’s investigational anti-programmed cell death protein 1…
The Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Novartis’s Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.
STADA Arzneimittel AG has appointed Engelbert Coster Tjeenk Willink as Chief Executive Officer with immediate effect.
NOXXON Pharma, a biotechnology company whose core focus is on improving cancer treatment by targeting the tumor microenvironment, has treated first patients in its Phase 1/2 clinical trial in patients with metastatic colorectal and pancreatic cancer at the National Center for Tumor Diseases in Heidelberg, Germany.